Effects of endothelial nitric oxide synthase, α-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide

American Journal of Hypertension

Volumn 16, Issue 10, 2003, Pages 834-839

  Turner, Stephen T ^a   Chapman, Arlene B ^b   Schwartz, Gary L ^a   Boerwinkle, Eric ^c  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Blood pressure; Diuretic; Genetics; Hypertension; Pharmacology; Polymorphism

Indexed keywords

ADDUCIN; ANTIHYPERTENSIVE AGENT; ARGININE; ASPARTIC ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; GLUTAMIC ACID; GLYCINE; HYDROCHLOROTHIAZIDE; LIPOPROTEIN LIPASE; NITRIC OXIDE SYNTHASE; SERINE; THIAZIDE DIURETIC AGENT; TRYPTOPHAN;

ADULT; AGE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; COVARIANCE; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; ETHNIC GROUP; FEMALE; GENDER; GENETIC CODE; GENETIC VARIABILITY; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SAMPLE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 0141674749     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)01011-2     Document Type: Article

References (20)

1. Meissner I, Whisnant JP, Sheps SG, Schwartz GL, O'Fallon WM, Covalt JL, Sicks JD, Bailey KR, Wiebers DO: Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999;34:466-471.
2. Laragh JH, Lamport B, Sealey J, Alderman MH: Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988;12:223-226.
3. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
4. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
5. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera, R, Stella P, Troffa C, Zagato L, Bianchi G: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-1357.
6. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT, Jr., Rosendaal FR: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002;287:1680-1689.
7. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001;37:739-743.
8. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E: Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002;62:1718-1723.
9. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST: Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002;61:1047-1055.
10. Turner S, Boerwinkle E, Sing C: Context-dependent associations of the ACE I/D polymorphism with blood pressure. Hypertension 1999;34:773-778.
11. Melton LJ 3rd: History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274.
12. Takanohashi A, Tojo A, Kobayashi N, Yagi S, Matsuoka H: Effect of trichlormethiazide and captopril on nitric oxide synthase activity in the kidney of deoxycorticosterone acetate-salt hypertensive rats. Jpn Heart J 1996;37:251-259.
13. Bragulat E, de la Sierra A, Antonio MT, Coca A: Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 2001;37:444-448.
14. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J: Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000;97:2832-2835.
15. Bianchi G, Tripodi G, Casari G, Salardi S, Barber B, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, Pinna L, Baralle F, Ferrari P: Two point mutations within the adducin gene are involved in blood pressure variation. Proc Natl Acad Sci 1994;91:3999-4003.
16. Bray MS, Li L, Turner ST, Kardia SL, Boerwinkle E: Association and linkage analysis of the alpha-adducin gene and blood pressure. Am J Hypertens 2000;13:699-703.
17. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, Groop L: Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-190.
18. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E: Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000;101:2877-2882.
19. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR: The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001;60:293-300.
20. Sing C, Boerwinkle E, Turner S: Genetics of primary hypertension. Clin Exp Hypertens 1986;8:623-651.